A postdoctoral research station is an organization approved by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee to recruit and train postdoctoral researchers in enterprises and scientific research and production institutions. It is an effective carrier to promote the integration of industry, academia and research and enhance the independent innovation capabilities of enterprises. The approval of the establishment of the postdoctoral research station is not only a recognition of GeneCradle's consistent adherence to the concept of independent innovation and the company's scientific research strength and level, but also an important boost to GeneCradle's future development. GeneCradle will further broaden the channels to attract high-level talents, deepen the cultivation of scientific research talents' innovative capabilities, build the company's talent pool and knowledge base, and also look forward to more elite talents joining the company's postdoctoral research station to jointly enhance the company's core innovation in the field of gene therapy-related technologies. At the "Postdoctoral Power Promotion Conference in the Process of Chinese Modernization", the Beijing Municipal Bureau of Human Resources and Social Security awarded plaques to the city's new postdoctoral stations and innovation practice bases. Leaders of the Beijing Economic and Technological Development Zone Social Affairs Bureau attended the awarding ceremony and took photos with representatives of the station-building companies.
About GeneCradle
Beijing GeneCradle Technology Co., Ltd. is a national high-tech enterprise with AAV vector delivery technology-mediated gene therapy drug development as its core business. Its mission is to promote China's rare disease gene drugs from basic to clinical and market, benefiting patients and families. The company focuses on the development of gene therapy drugs in the fields of hereditary neuromuscular diseases, genetic metabolic diseases, lysosomal diseases and ophthalmic diseases. By promoting the development and clinical application of rare disease gene drugs, it has a deeper understanding of life and health, and has transitioned gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic diseases and other major diseases.